Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Walter Canonica

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
Journal of Aerosol Medicine and Pulmonary Drug Delivery|June 22, 2011
Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPDVito Brusasco, G Walter Canonica, Roberto Dal Negro, et al.
The Lancet. Respiratory Medicine|December 10, 2023
Pioneering a paradigm shift in asthma management: remission as a treatment goalMarek Lommatzsch, Roland Buhl, G Walter Canonica, et al.
Allergy|August 30, 2021
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trialsJoaquim Mullol, Tanya M Laidlaw, Claus Bachert, et al.
Expert Opinion on Pharmacotherapy|March 10, 2015
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gapsJean Bousquet, Claus Bachert, Jonathan Bernstein, et al.
Clinical and Translational Allergy|August 19, 2015
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticariaKarsten Weller, Marcus Maurer, Clive Grattan, et al.
International Archives of Allergy and Immunology|November 28, 2012
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of MonacoG Walter Canonica, Carlos E Baena-Cagnani, Enrico Compalati, et al.
The Journal of Allergy and Clinical Immunology|December 28, 2024
Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paperJorge Sánchez, Helena Pite, René Maximiliano Gómez, et al.
International Archives of Allergy and Immunology|May 9, 2013
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisEli Meltzer, Paul Ratner, Claus Bachert, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel ReportMoisés A Calderon, Susan Waserman, David I Bernstein, et al.
Allergy|July 14, 2023
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paperJasper Kappen, Zuzana Diamant, Ioana Agache, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
Journal of Aerosol Medicine and Pulmonary Drug Delivery|June 22, 2011
Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPDVito Brusasco, G Walter Canonica, Roberto Dal Negro, et al.
The Lancet. Respiratory Medicine|December 10, 2023
Pioneering a paradigm shift in asthma management: remission as a treatment goalMarek Lommatzsch, Roland Buhl, G Walter Canonica, et al.
Allergy|August 30, 2021
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trialsJoaquim Mullol, Tanya M Laidlaw, Claus Bachert, et al.
Expert Opinion on Pharmacotherapy|March 10, 2015
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gapsJean Bousquet, Claus Bachert, Jonathan Bernstein, et al.
Clinical and Translational Allergy|August 19, 2015
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticariaKarsten Weller, Marcus Maurer, Clive Grattan, et al.
International Archives of Allergy and Immunology|November 28, 2012
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of MonacoG Walter Canonica, Carlos E Baena-Cagnani, Enrico Compalati, et al.
The Journal of Allergy and Clinical Immunology|December 28, 2024
Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paperJorge Sánchez, Helena Pite, René Maximiliano Gómez, et al.
International Archives of Allergy and Immunology|May 9, 2013
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisEli Meltzer, Paul Ratner, Claus Bachert, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 19, 2020
Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel ReportMoisés A Calderon, Susan Waserman, David I Bernstein, et al.
Allergy|July 14, 2023
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paperJasper Kappen, Zuzana Diamant, Ioana Agache, et al.
Pageof 16